相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy
Jinshui Fan et al.
BLOOD (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review
Amer Beitinjaneh et al.
LEUKEMIA RESEARCH (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeted Signal Transduction Therapies in Myeloid Malignancies
Emma Scott et al.
CURRENT ONCOLOGY REPORTS (2010)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia
Yuichi Ishikawa et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress
K. Wolyniec et al.
ONCOGENE (2009)
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Annahita Sallmyr et al.
BLOOD (2008)
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens
Keith Pratz et al.
LEUKEMIA & LYMPHOMA (2008)
Characterization of acute myeloid leukemia with PTPN11 mutation:: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD
H-A Hou et al.
LEUKEMIA (2008)
CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment
J. Juarez et al.
LEUKEMIA (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
FLT3 inhibition in acute myeloid leukaemia
Steven Knapper
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Synergistic effect of arsenic trioxide and Flt3 inhibition on cells with Flt3 internal tandem duplication
Shinichiro Takahashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias
M Inomata et al.
LEUKEMIA RESEARCH (2006)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
Christian Thiede et al.
BLOOD (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells
S Takahashi
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway
Q Yao et al.
LEUKEMIA (2005)
AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication
S Takahashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
FLT3 tyrosine kinase inhibitors
M Levis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Runx1/UAML1 in normal and abnormal hematopoiesis
T Yamagata et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
C Choudhary et al.
BLOOD (2005)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
FLT-3: a new focus in the understanding of acute leukemia
A Markovic et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase
Y Komeno et al.
LEUKEMIA (2005)
FIG ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1α(CXCL12)/CXCR4 axis
S Fukuda et al.
BLOOD (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies
D Douer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematofogic malignancies
M Wadleigh et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins
B Scheijen et al.
ONCOGENE (2004)
CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice
S Tavor et al.
CANCER RESEARCH (2004)
Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5
S Takahashi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression
R Zheng et al.
BLOOD (2004)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
K Ozeki et al.
BLOOD (2004)
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy
T Taketani et al.
BLOOD (2004)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations
MP Oyarzo et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
KWH Yee et al.
BLOOD (2004)
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development
Y Ming et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia
EJC Rombouts et al.
BLOOD (2004)
FLT3 mutations are associated with other molecular lesions in AML
MJ Carnicer et al.
LEUKEMIA RESEARCH (2004)
The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT
S Takahashi et al.
BLOOD (2004)
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1
F Rosenbauer et al.
NATURE GENETICS (2004)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
R Zheng et al.
BLOOD (2004)
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3
P George et al.
CANCER RESEARCH (2004)
STAT proteins:: From normal control of cellular events to tumorigenesis
V Calò et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3)
K Murata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia
C Steudel et al.
GENES CHROMOSOMES & CANCER (2003)
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
A Gazit et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
K Spiekermann et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
N Noguera et al.
LEUKEMIA (2002)
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2002)
The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein
S Takahashi et al.
LEUKEMIA (2002)
Bis(1 H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3
S Teller et al.
LEUKEMIA (2002)
Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
Y Minami et al.
LEUKEMIA (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
LM Kelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines
MB Miranda et al.
LEUKEMIA (2002)
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
LM Kelly et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease
M Nakao et al.
LEUKEMIA (2000)
分享论文
